ZBIO - Latest News
Zenas BioPharma, Inc. (ZBIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.15B. Beta to the broader market is -0.69.
The article list below shows the most recent ZBIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ZBIO Headlines
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
fool.com - Jun 21, 2026
CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1. 01 million on May 18, 2026.
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Jun 17, 2026
WALTHAM, Mass. , June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
globenewswire.com - Jun 11, 2026
WALTHAM, Mass. , June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
globenewswire.com - Jun 2, 2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the tot
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
globenewswire.com - Jun 2, 2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the tot
How News Affects ZBIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ZBIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ZBIO news questions
- What is the latest ZBIO news headline?
- The most recent ZBIO headline (Jun 21, 2026) is "Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ZBIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ZBIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ZBIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.